Biotech clinical news summary, 30 October

Today in brief

Geron discontinued its Phase III IMpactMF trial after an independent committee concluded Rytelo was unlikely to meet the overall-survival goal.1

Geron stops Rytelo trial after committee sees limited survival potential

Geron stopped the Phase III IMpactMF trial of Rytelo after its independent monitoring committee judged the drug unlikely to improve overall survival enough to meet the primary endpoint.1 The trial enrolled 327 people with myelofibrosis, and the committee found no new safety concerns in this group.1

Geron said it will assess the results for insights relevant to future myelofibrosis research.1 The company plans to study Rytelo with Jakafi in frontline myelofibrosis in the Phase I IMproveMF study.1

Also worth knowing

Nuvation Bio plans to add trial sites in France, Germany, Italy, Spain, Sweden and the UK to its Phase III SIGMA study of safusidenib for IDH1-mutant glioma.2
Starton Therapeutics and Stanford School of Medicine agreed to test STAR-LLD with a CAR-T therapy in an investigator-led study of relapsed or refractory multiple myeloma.3

Also published

What Needs to Happen Beyond the Clinical Trial Modernization Act Applied Clinical Trials
Post-Exposure Prophylaxis Is the Missing Piece: Q&A with Florin Draica Pharmaceutical Executive
ACT Brief: Community Research Access, Trustworthy AI Assistants, and Individualized Gene Editing Guidance Applied Clinical Trials
Closing the Pediatric Evidence Gap Pharmaceutical Executive
How Embedding Research Into Routine Community Care Changes Who Gets Access Applied Clinical Trials
How Preventative Medications May Impact the Lingering Impact of COVID-19 Pharmaceutical Executive